A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Subjects Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
Latest Information Update: 15 Feb 2025
Price :
$35 *
At a glance
- Drugs CNP 103 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Cour Pharmaceutical Development
- 04 Feb 2025 According to a Cour Pharmaceutical Development media release, the USFDA has cleared its IND application for CNP-103, and this trial is expected to be initiated later this year.
- 24 Jan 2025 New trial record